Kidney and sickle cell disease

Renal affection in sickle cell diseased children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202511496294441

Enrollment

Registered

2025-11-14

Start date

2025-11-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Haematological Disorders

Interventions

urine analysis and kidney function tests

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age between 3 and 18 years. Diagnosed with one of the following: Sickle cell anemia (HbSS) Sickle cell trait Sickle beta thalassemia (HbSß° or HbSß?)

Exclusion criteria

Exclusion criteria: 1. Patients with hemolytic anemias other than sickle cell. 2. Patients with known renal anomalies. 3. Patients refused to participate in the study.

Design outcomes

Primary

Measure	Time frame
Prevalence of renal affection in pediatric patients with sickle cell disease (SCD) Description: Renal affection (composite outcome) will be defined as the presence of one or more of the following abnormalities: 1. Elevated morning urine albumin-to-creatinine ratio (ACR) > 30 mg/g 2. Abnormal kidney function tests (elevated serum creatinine and/or blood urea nitrogen above age-adjusted reference ranges) 3. Abnormal renal imaging findings (ultrasound, and intravenous pyelogram or CT scan when clinically indicated) The primary outcome will be the percentage of participants who meet any of these criteria during the study period.	—

Measure

Time frame

Prevalence of renal affection in pediatric patients with sickle cell disease (SCD) Description: Renal affection (composite outcome) will be defined as the presence of one or more of the following abnormalities: 1. Elevated morning urine albumin-to-creatinine ratio (ACR) > 30 mg/g 2. Abnormal kidney function tests (elevated serum creatinine and/or blood urea nitrogen above age-adjusted reference ranges) 3. Abnormal renal imaging findings (ultrasound, and intravenous pyelogram or CT scan when clinically indicated) The primary outcome will be the percentage of participants who meet any of these criteria during the study period.

—

Secondary

Measure	Time frame
Association between adherence to hydroxyurea therapy and renal affection Description: Evaluate the association between adherence to hydroxyurea treatment (assessed by pill count, refill records, or patient self-report) and the presence of renal affection.	—

Countries

Egypt

Contacts

Public ContactHamdy Ghazaly

Professor

ghazally@aun.edu.eg01001296603

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026